PO.BCS01.07 · 生物信息与计算
Deep learning integration of molecular and histopathological data for prognostic stratification in non small cell lung cancer
作者与单位
摘要 Abstract
Background: Co-mutations, PD-L1 and TILs are key NSCLC biomarkers. We applied deep learning to a multimodal patient cohort to identify prognostic patterns integrating morphology, mutations, and clinical features.
Methods: 367 NSCLC patients from 18 Hellenic Cooperative Oncology Group-affiliated centers were retrospectively assessed for PD-L1 status (Dako 22C3 pharmDx), TILs (H&E slides), and somatic pathogenic variants with a 38-gene next-generation sequencing (NGS) panel. Whole slide images (WSI) were digitized by an optical microscope scanner. Ten pathology foundation models were benchmarked for predicting mutation, co-mutation, PD-L1 and TILs status. Mutated genes with >5% prevalence were considered for mutation and co-mutation endpoints ( TP53 , KRAS , STK11 , PTEN , EGFR ). A vision transformer model was trained on WSI features to predict endpoints and evaluate AUROC. Kaplan-Meier analysis assessed prognostic relevance of models and top feature tiles from model attention maps provided morphological explainability. The STAMP digital pathology pipeline supported feature extraction and model training.
Results: Single mutation models yielded AUROC scores of 0.6-0.85, with STK11 prediction from HOptimus1 features highest. Co-mutation models produced AUROC scores of 0.69-0.77 with EGFR-TP53 prediction from Uni2 features the best. The KRAS-TP53 co-mutation model (AUROC 0.69, Uni2) showed significant separation in overall survival curves (p=0.05) between classes. Best-performing PD-L1 and TIL models also demonstrated significant survival separation (p=0.005 and p=0.05).
Conclusion: Findings demonstrate the potential of pathology foundation models to derive complex clinically-relevant prognostic models for NSCLC with multimodal explainability.
AUROC by endpoint and foundation model TP53 KRAS PTEN STK11 EGFR EGFR+TP53 KRAS+STK11 KRAS+TP53 PTEN+TP53 TILs PD-L1 Conch1.5 0.48 0.62 0.24 0.79 0.61 0.58 0.72 0.26 0.41 0.65 0.49 CTranspath 0.52 0.77 0.45 0.17 0.5 0.57 0.33 0.68 0.34 0.6 0.6 Dinobloom 0.43 0.45 0.51 0.58 0.46 0.75 0.75 0.68 0.38 0.65 0.73 Gigapath 0.47 0.5 0.44 0.84 0.31 0.61 0.37 0.12 0.63 0.65 0.6 HOptimus0 0.5 0.72 0.56 0.65 0.55 0.61 0.63 0.08 0.48 0.62 0.65 HOptimus1 0.57 0.66 0.43 0.85 0.64 0.63 0.52 0.39 0.28 0.61 0.55 Musk 0.49 0.49 0.51 0.77 0.54 0.61 0.53 0.58 0.43 0.7 0.54 Plip 0.55 0.52 0.5 0.52 0.43 0.48 0.72 0.44 0.74 0.67 0.6 Uni 0.61 0.58 0.6 0.56 0.48 0.7 0.45 0.26 0.46 0.66 0.61 Uni2 0.52 0.69 0.51 0.81 0.61 0.77 0.41 0.69 0.57 0.59 0.64
利益披露 Disclosure
S. Jayabalan,
AstraZeneca Employment.
K. Efthymiadis,
HeSMO (Hellenic Society of Medical Oncology) ).
A. Eliades, None..
K. Papadopoulou, None..
A. Pouliakis, None..
E. Fountzilas, None..
S. Lampaki, None..
M. Bobos, None..
A. Goussia, None..
S. Meditskou, None..
K. Kyritsis, None..
H. Linardou, None..
G. Pentheroudakis, None..
D. Bafaloukos, None..
D. Pectasides, None..
E. Samantas, None..
Z. I. Carrero, None..
G. Fountzilas, None.
J. N. Kather,
AstraZeneca ), Other, Consulting.
Panakeia Other.
Bioptimus Other, Consulting.
StratifAI Stock.
Synagen Stock.
Spira Labs Stock.
GSK ).